| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Biotricity Inc (NASDAQ:BTCY) announced the upcoming release of the Biocare Cardiac application to be used with Samsung's Galaxy Watch4 series.
Biocare is a personal cardiac health application for individuals diagnosed with or at risk for cardiovascular disease.
The application continuously collects users' daily activities and provides critical information on their heart performance to understand better and manage heart conditions.
The new application is designed to help patients between doctor visits by engaging them in lifestyle management activities to help their doctors make diagnoses augmented with daily medical data related to ECG, SpO2, heart rate, weight, and details on fitness and exercise.
"Biocare cardiac is a key component of Biotricity's long term vision to follow cardiac patients from diagnostics to disease management. The Biocare cardiac app will integrate Biotricity's existing and future products, alongside leading industry solutions for fitness and lifestyle, to create a cohesive view of an individual's health," Biotricity CEO told Benzinga.
The application can be used as part of Biotricity's complete cardiac solution, including:
Galaxy Watch4 Series is equipped with an advanced suite of health and wellness features, including the ability to detect an AFib irregular heartbeat, measure blood oxygen level, calculate body composition, and track physical activity.
This is Samsung's first smartwatch to feature the new Wear OS Powered by Samsung, built jointly with Google.
Price Action: BTCY shares are up 11.6% at $3.08 during the market session on the last check Thursday.
